Current treatment options for ccRCC based on patient and disease factors
Matthew Campbell, MD, MS, and Rana McKay, MD, offer a concise review of existing treatment approaches for clear cell renal cell carcinoma across risk categories, along with considerations for sequencing therapies.
- Dr Campbell: Please provide a brief overview of current treatment options available to intermediate/poor risk and favorable risk ccRCC.
- What patient and/or disease factors do you consider when choosing appropriate treatment?
Kilari Discusses Frontline Treatment Selection Factors for mRCC
June 27th 2024During a Case-Based Roundtable® event, Deepak Kilari, MD, discussed with participants how updated data on frontline regimens affects their choice of therapy for patients with metastatic clear cell renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
